Sirtex

Medical device company specializing in cancer treatment

Sirtex Medical logo

Sirtex Medical Limited is a global healthcare business that specializes in the development and commercialization of effective liver cancer treatments. The company is renowned for its innovative approach to treating metastatic colorectal cancer and other liver tumors using Selective Internal Radiation Therapy (SIRT) with SIR-Spheres® Y-90 resin microspheres.

History

Sirtex was founded in 1997 in Australia and has since expanded its operations internationally. The company was established with the goal of providing innovative treatment options for patients with liver cancer, a field that had limited therapeutic options at the time. Over the years, Sirtex has focused on research and development to enhance the efficacy and safety of its products.

Technology

File:Torsospheres.jpg

SIR-Spheres microspheres used in treatment

The core technology of Sirtex is based on SIR-Spheres Y-90 resin microspheres, which are used in Selective Internal Radiation Therapy (SIRT). This treatment involves the delivery of millions of tiny radioactive beads directly to the liver tumors via the hepatic artery. The microspheres emit beta radiation, which helps to destroy cancer cells while sparing healthy liver tissue.

SIR-Spheres Y-90 Resin Microspheres

SIR-Spheres are biocompatible resin microspheres that contain the radioactive isotope Yttrium-90. The microspheres are injected into the liver's blood supply, where they become lodged in the small blood vessels surrounding the tumor. This localized delivery allows for a high dose of radiation to be administered directly to the tumor, minimizing exposure to surrounding healthy tissue.

Applications

Sirtex's SIR-Spheres are primarily used in the treatment of unresectable liver tumors, including those resulting from metastatic colorectal cancer and hepatocellular carcinoma. The treatment is often used in conjunction with other therapies, such as chemotherapy, to improve patient outcomes.

Global Presence

Sirtex has a significant global presence, with offices and distribution networks in the United States, Europe, and Asia. The company collaborates with leading medical institutions and healthcare providers worldwide to ensure the availability of its products to patients in need.

Research and Development

Sirtex is committed to ongoing research and development to enhance the effectiveness of its treatments and explore new applications for its technology. The company invests in clinical trials and collaborates with academic and research institutions to advance the field of interventional oncology.

Related pages

• Liver cancer
• Radiation therapy
• Interventional radiology
• Metastatic colorectal cancer